Atorvastatin Sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 593039

CAS#: 134523-01-6 (sodium)

Description: Atorvastatin sodium is a competitive inhibitor of HMG-CoA reductase, increasing expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes. Atorvastatin sodium pretreatment attenuates ischemic brain edema by suppressing aquaporin 4.

Chemical Structure

img
Atorvastatin Sodium
CAS# 134523-01-6 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 593039
Name: Atorvastatin Sodium
CAS#: 134523-01-6 (sodium)
Chemical Formula: C33H34FN2NaO5
Exact Mass: 0.00
Molecular Weight: 580.630
Elemental Analysis: C, 68.26; H, 5.90; F, 3.27; N, 4.82; Na, 3.96; O, 13.78

Price and Availability

Size Price Availability Quantity
250mg USD 450 2 Weeks
500mg USD 800 2 Weeks
1g USD 1350 2 Weeks
Bulk inquiry

Related CAS #: 134523-03-8 (calcium)   344423-98-9 (calcium trihydrate)   134523-00-5 (free acid)   134523-01-6 (sodium)   874114-41-7 (magnesium)   1035609-19-8 (magnesium trihydrate)   609843-23-4 (lysine)   1072903-92-4 (strontium)  

Synonym: Atorvastatin Sodium; Lipitor

IUPAC/Chemical Name: Sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate

InChi Key: VVRPOCPLIUDBSA-CNZCJKERSA-M

InChi Code: InChI=1S/C33H35FN2O5.Na/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);/q;+1/p-1/t26-,27-;/m1./s1

SMILES Code: CC(C)c1c(c(c(n1CC[C@H](C[C@H](CC(=O)[O-])O)O)c2ccc(cc2)F)c3ccccc3)C(=O)Nc4ccccc4.[Na+]

Appearance: Pale Yellow Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 580.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wang Y, Jin Y, Yun X, Wang M, Dai Y, Xia Y. Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. Life Sci. 2018 Aug 7. pii: S0024-3205(18)30458-2. doi: 10.1016/j.lfs.2018.08.012. [Epub ahead of print] PubMed PMID: 30096386.

2: Cheng ZJ, Dai TM, Shen YY, He JL, Li J, Tu JL. Atorvastatin Pretreatment Attenuates Ischemic Brain Edema by Suppressing Aquaporin 4. J Stroke Cerebrovasc Dis. 2018 Aug 6. pii: S1052-3057(18)30380-X. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.011. [Epub ahead of print] PubMed PMID: 30093197.

3: Hari P, Khandelwal P, Satpathy A, Hari S, Thergaonkar R, Lakshmy R, Sinha A, Bagga A. Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial. Pediatr Nephrol. 2018 Aug 8. doi: 10.1007/s00467-018-4036-x. [Epub ahead of print] PubMed PMID: 30091061.

4: Choi Y, Lee S, Jang IJ, Yu KS. Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers. Drug Des Devel Ther. 2018 Jul 24;12:2301-2309. doi: 10.2147/DDDT.S165171. eCollection 2018. PubMed PMID: 30087555; PubMed Central PMCID: PMC6063220.

5: Mantsiou C, Tziomalos K. Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients. Curr Med Res Opin. 2018 Aug 8:1-5. doi: 10.1080/03007995.2018.1510224. [Epub ahead of print] PubMed PMID: 30086667.

6: Feng P, Zhao L, Guo F, Zhang B, Fang L, Zhan G, Xu X, Fang Q, Liang Z, Li B. The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins. Chem Biol Interact. 2018 Aug 4;293:115-123. doi: 10.1016/j.cbi.2018.07.022. [Epub ahead of print] PubMed PMID: 30086269.

7: Morotti K, Lopez J, Vaupel V, Swislocki A, Siegel D. Adherence to and Persistence With Statin Therapy in a Veteran Population. Ann Pharmacother. 2018 Aug 7:1060028018792702. doi: 10.1177/1060028018792702. [Epub ahead of print] PubMed PMID: 30084646.

8: Giustino G, Colantonio LD, Brown TM, Carson AP, Dai Y, Farkouh ME, Monda KL, Muntner P, Rosenson RS. Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. Cardiovasc Drugs Ther. 2018 Aug 4. doi: 10.1007/s10557-018-6816-8. [Epub ahead of print] PubMed PMID: 30078077.

9: Ye H, Wang S, Hu Y, He F, Ju J, Cui H, Chen X. Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography. Medicine (Baltimore). 2018 Aug;97(31):e11718. doi: 10.1097/MD.0000000000011718. PubMed PMID: 30075578.

10: Ren J, Liu W, Li GC, Jin M, You ZX, Liu HG, Hu Y. Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCε Pathway. Curr Med Sci. 2018 Jun;38(3):405-412. doi: 10.1007/s11596-018-1893-2. Epub 2018 Jun 22. PubMed PMID: 30074205.

11: Mathur M, Vemula KD. Investigation of different types of nano drug delivery systems of Atorvastatin for the treatment of Hyperlipidemia. Drug Dev Ind Pharm. 2018 Aug 3:1-36. doi: 10.1080/03639045.2018.1508225. [Epub ahead of print] PubMed PMID: 30073852.

12: Choi NY, Kim JY, Hwang M, Lee EH, Choi H, Lee KY, Lee YJ, Koh SH. Atorvastatin Rejuvenates Neural Stem Cells Injured by Oxygen-Glucose Deprivation and Induces Neuronal Differentiation Through Activating the PI3K/Akt and ERK Pathways. Mol Neurobiol. 2018 Aug 3. doi: 10.1007/s12035-018-1267-6. [Epub ahead of print] PubMed PMID: 30073508.

13: Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, Mao Y, Yuan X, Fei Z, Zhao Y, Yu X, Poon WS, Zhu X, Liu N, Kang D, Sun T, Jiao B, Liu X, Yu R, Zhang J, Gao G, Hao J, Su N, Yin G, Zhu X, Lu Y, Wei J, Hu J, Hu R, Li J, Wang D, Wei H, Tian Y, Lei P, Dong JF, Zhang J. Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. JAMA Neurol. 2018 Jul 30. doi: 10.1001/jamaneurol.2018.2030. [Epub ahead of print] PubMed PMID: 30073290.

14: Mylonaki I, Allémann E, Delie F, Jordan O. Imaging the porous structure in the core of degrading PLGA microparticles: The effect of molecular weight. J Control Release. 2018 Jul 30;286:231-239. doi: 10.1016/j.jconrel.2018.07.044. [Epub ahead of print] PubMed PMID: 30071251.

15: Nikolic Turnic TR, Jakovljevic V PhD, Djuric D, Jeremic N, Jeremic J, Milosavljevic I, Srejovic IM, Selakovic D, Zivkovic VI. EFFICENCY OF ATORVASTATIN AND SIMVASTATIN IN IMPROVING OF CARDIAC FUNCTION DURING THE DIFFERENT DEGREE OF HYPERHOMOCYSTEINEMIA. Can J Physiol Pharmacol. 2018 Aug 1. doi: 10.1139/cjpp-2018-0102. [Epub ahead of print] PubMed PMID: 30067069.

16: Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, Fischer MA, Gagne JJ, Connolly JG. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Saf. 2018 Aug 1. doi: 10.1007/s40264-018-0703-x. [Epub ahead of print] PubMed PMID: 30066315.

17: Dougherty JA. Atorvastatin-Associated Macroglossia in a Cardioembolic Stroke Patient. Ann Pharmacother. 2018 Jul 30:1060028018793111. doi: 10.1177/1060028018793111. [Epub ahead of print] PubMed PMID: 30058342.

18: Kleywegt S, Payne M, Ng F, Fletcher T. Environmental loadings of Active Pharmaceutical Ingredients from manufacturing facilities in Canada. Sci Total Environ. 2018 Jul 25;646:257-264. doi: 10.1016/j.scitotenv.2018.07.240. [Epub ahead of print] PubMed PMID: 30055488.

19: Sáfár Z, Jani M, Makai I, Fekete Z, Bui A, Molnár É, Pádár P, Pratt JR, Kis E, Beéry E, Krajcsi P. Correlation Analysis of Potential BCRP Probes in Different Monolayer Systems. J Pharm Sci. 2018 Jul 25. pii: S0022-3549(18)30449-0. doi: 10.1016/j.xphs.2018.07.014. [Epub ahead of print] PubMed PMID: 30055222.

20: Subhan M, Faryal R, Macreadie I. Statin resistance in Candida glabrata. Biotechnol Lett. 2018 Jul 27. doi: 10.1007/s10529-018-2597-1. [Epub ahead of print] PubMed PMID: 30054755.